OBJECTIVE: We determined whether the prostaglandin inhibitor sulindac crosses the @entity1 placenta. METHODS: The recirculating single-cotyledon placenta model was used to characterize the maternal-to-fetal and fetal-to-maternal transport of @entity3209 -labeled sulindac in normal term placentas perfused immediately after delivery. @entity4591 was added as a standard for simple diffusion. Serial samples were taken from both reservoirs during each 3-hour perfusion. Transport was calculated using liquid scintillation spectrometry for @entity3209 -labeled sulindac and high-performance liquid chromatography for antipyrine. RESULTS: There was significant maternal-to-fetal transfer of sulindac. The mean (+/- SD) transfer at 2 hours was 7.22 +/- 2.57%. The fetal-to-maternal transfer was similar at 10.75 +/- 3.80%. The mean maternal/fetal concentration ratio of sulindac was 0.42 at 3 hours. Placental uptake ranged from 24-45 ng/g of placenta. CONCLUSIONS: Sulindac crosses the @entity1 placenta in small but significant amounts. The transport is similar in both directions, implying simple diffusion.

XXXX placental transfer of the prostaglandin inhibitor sulindac using an in vitro model.

@entity1 :: ('9606', 'Species') :: ['human'] @entity4591 :: ('MESH:D000983', 'Chemical') :: ['Antipyrine'] @entity3209 :: ('CHEBI:36927', 'Chemical') :: ['14C']
@entity1 :: (9606,Species) :: ['Human']
